{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Factor", "query": { "condition": "Growth Factor" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 930, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Growth+Factor&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T01:51:26.744Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05973773", "title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2023-12-18", "completion_date": "2027-05-27", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 9, "location_summary": "Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more", "locations": [ { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973773" }, { "nct_id": "NCT00783172", "title": "Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Opioid Growth Factor (OGF)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2009-01", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2018-09-06", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 2, "location_summary": "Allentown, Pennsylvania • Hershey, Pennsylvania", "locations": [ { "city": "Allentown", "state": "Pennsylvania" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00783172" }, { "nct_id": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Neoplasms", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2018-10-05", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 23, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615326" }, { "nct_id": "NCT00658658", "title": "Panitumumab in Children With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Panitumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 31, "start_date": "2008-03", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-05-18", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 11, "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00658658" }, { "nct_id": "NCT07169279", "title": "Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib is provided as a single dose of minitablets for oral administration", "type": "DRUG" }, { "name": "Infigratinib is provided as sprinkle capsules for daily oral administration", "type": "DRUG" }, { "name": "Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "32 Months", "sex": "ALL", "summary": "0 Years to 32 Months" }, "enrollment_count": 77, "start_date": "2025-11-19", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 3, "location_summary": "Oakland, California • Baltimore, Maryland • Madison, Wisconsin", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169279" }, { "nct_id": "NCT03955913", "title": "A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Urothelial Cancer", "Receptors, Fibroblast Growth Factor" ], "interventions": [ { "name": "Archival Tumor Tissue Sample", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3679, "start_date": "2019-08-01", "completion_date": "2022-09-19", "has_results": false, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 23, "location_summary": "Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Chicago Ridge", "state": "Illinois" }, { "city": "Brandywine", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955913" }, { "nct_id": "NCT00005987", "title": "Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "recombinant interferon alfa", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 87, "start_date": "2000-08", "completion_date": "2003-07", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005987" }, { "nct_id": "NCT00785538", "title": "A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "IMC-A12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2005-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Seattle, Washington", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00785538" }, { "nct_id": "NCT00362986", "title": "Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatologic Complications", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sunscreen", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 116, "start_date": "2006-10", "completion_date": "2009-10", "has_results": false, "last_update_posted_date": "2016-12-13", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 208, "location_summary": "Jacksonville, Florida • Aurora, Illinois • Bloomington, Illinois + 130 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" }, { "city": "Carthage", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362986" }, { "nct_id": "NCT02404870", "title": "Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2014-09-16", "completion_date": "2019-09-03", "has_results": false, "last_update_posted_date": "2025-03-04", "last_synced_at": "2026-09-06T01:51:26.744Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02404870" } ] }